Skip to main content
105 search results for:

DPP-4 inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 10-06-2022 | SGLT2 inhibitors | News | Article
    News in brief

    SGLT2 inhibitors linked to lower gout risk than DPP-4 inhibitors

    SGLT2 inhibitors are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

  2. 02-08-2021 | COVID-19 | News | Article

    No need to discontinue DPP-4 inhibitors during hospitalization for COVID-19

    Results from the CORONADO study indicate that use of DPP-4 inhibitors does not affect outcomes for people with type 2 diabetes admitted to hospital with COVID-19.

  3. 06-12-2018 | Empagliflozin | Article

    Cardiovascular safety of empagliflozin versus dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes: Systematic literature review and indirect comparisons

    In this work, we aimed to assess the relative treatment effects of empagliflozin versus sitagliptin and saxagliptin (dipeptidyl peptidase-4 (DPP-4)

  4. 06-01-2018 | DPP-4 inhibitors | Article

    Comparative effectiveness of DPP-4 inhibitors versus sulfonylurea for the treatment of type 2 diabetes in routine clinical practice: A retrospective multicenter real-world study

    Introduction: DPP-4 inhibitors (DPP4i) and sulfonylureas are popular second-line therapies for type 2 diabetes (T2D), but there is a paucity of

  5. 12-05-2022 | SGLT2 inhibitors | News | Article

    Algorithm could optimize SGLT2 vs DPP-4 inhibitor decisions in clinical practice

    An algorithm based on real-world clinical data could support decisions between use of SGLT2 inhibitors and DPP-4 inhibitors in people with type 2 diabetes.

  6. 08-31-2023 | Type 2 diabetes | News | Article

    Pragmatic trial suggests best cardioprotective agents for type 2 diabetes

    SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

  7. 08-25-2022 | Physical activity | News | Article

    Initiating glucose-lowering therapy may be linked to a reduction in physical activity

    Starting treatment with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors is associated with a reduction in physical activity levels among some people with type 2 diabetes, researchers report.

  8. 05-26-2023 | Type 2 diabetes | News | Article

    Common antidiabetic add-on therapies offer similar renal outcomes

    “These results suggest that neither DPP-4 inhibitor, GLP-1 receptor agonist, sulfonylurea, nor basal insulin has a substantial comparative advantage when added to metformin for preventing the development or progression of DKD in [type 2 diabetes] in the first decade after diagnosis,” Wexler et al conclude.

  9. 04-24-2023 | Sulfonylureas | News | Article

    Sulfonylureas ‘unlikely’ to increase CV, mortality risk in real-world use

    The results of the multivariable analysis showed no significantly higher risks in the SU group compared with DPP-4 inhibitors and TZD.

  10. 09-01-2022 | Metformin | News | Article

    People with type 2 diabetes and CKD missing out on renoprotective drugs

    People with type 2 diabetes and chronic kidney disease are substantially less likely to initiate SGLT2 inhibitors than those with normal kidney function, despite their proven renoprotective benefits, research shows.

  11. 06-30-2022 | Adverse effects | News | Article

    Meta-analysis flags cholecystitis risk with DPP-4 inhibitor treatment

    People taking dipeptidyl peptidase-4 inhibitors to treat type 2 diabetes may have an increased risk for cholecystitis, especially with longer duration of treatment, show findings of a meta-analysis.

  12. 01-15-2021 | Heart failure | News | Article

    SGLT2 inhibitor cardiac benefits extend to older people in real world

    SGLT2 inhibitors are associated with lower rates of heart failure hospitalization, all-cause mortality, and hypoglycemia, but higher rates of diabetic ketoacidosis, when compared with DPP-4 inhibitors in older adults with type 2 diabetes, suggests a Canadian study.

  13. 04-05-2022 | Medications | At a glance | Article
    At a glance

    Medications for pediatric type 2 diabetes: What’s approved, what’s coming up?

    Related article: Round-up of the GLP-1 receptor agonist CV outcome trials DPP-4 inhibitors Use of dipeptidyl peptidase (DPP)-4 inhibitors is well established in adults with type 2 diabetes.

  14. 10-08-2020 | SGLT2 inhibitors | News | Article
    News in brief

    More real-world evidence for SGLT2 inhibitor cardioprotection

    Further real-world evidence demonstrates the positive cardiovascular effects of SGLT2 inhibitors in people with type 2 diabetes, in this case when compared against DPP-4 inhibitors.

  15. 10-02-2020 | COVID-19 | News | Article

    SGLT2 inhibitors unlikely to increase SARS-CoV-2 infection risk

    The incidence of COVID-19 is no higher among people taking SGLT2 inhibitors than those taking DPP-4 inhibitors, research shows.

  16. 06-29-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

  17. 08-18-2021 | DPP-4 inhibitors | News | Article
    News in brief

    DPP-4 inhibitor use linked to better Alzheimer’s disease outcomes

    Use of dipeptidyl peptidase-4 inhibitors may reduce amyloid burden in people with cognitive impairment due to Alzheimer’s disease, suggests an imaging study.

  18. 10-13-2021 | Liraglutide (T2DM) | News | Article

    Liraglutide add-on may offer better control than OADs in type 2 diabetes

    Post-hoc analyses comparing liraglutide with SGLT2 inhibitors, DPP-4 inhibitors, and sulfonylureas separately showed similar outcomes.

  19. 05-22-2019 | Sulfonylureas | Editorial | Article

    The CAROLINA trial: Make or break for sulfonylureas?

    Diabetologist Sanjay Kalra puts the CAROLINA trial into historical context and considers the present-day implications for the use of DPP-4 inhibitors and sulfonylureas.

  20. 08-28-2018 | Oral combination medications | Article

    Efficacy and safety of initial combination therapy in treatment-naïve type 2 diabetes patients: A systematic review and meta-analysis

    Cai X et al. Diabetes Ther 2018. doi: 10.1007/s13300-018-0493-2

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.